Manufacturer's ref.No: (b)(4).This complaint is from a literature source: hayasaka k, sasaki t, shirai y, shimosato h, tahara t, segami s, nagasawa r, akimoto k, yabe k, toya c, watanabe k, yamashita s, suzuki m, sugiyama k, yamauchi y, okishige k, goya m, sasano t.A novel catheter ablation strategy for non-paroxysmal atrial fibrillation combining cryoballoon, radiofrequency, and marshall-vein ethanol ablations.Pacing clin electrophysiol.2023 may 2.Doi: 10.1111/pace.14709.Epub ahead of print.Pmid: 37129189.Since no device has been received for analysis, no product investigation can be performed, and the customer complaint cannot be confirmed.Manufacturing record evaluation (mre) cannot be conducted because no lot number was not provided by the customer.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster inc., or its employees that the report constitutes an admission that the product, biosense webster inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Note: the literature article's electronic file size is too large to be attached and submitted.
|
This complaint is from a literature source: hayasaka k, sasaki t, shirai y, shimosato h, tahara t, segami s, nagasawa r, akimoto k, yabe k, toya c, watanabe k, yamashita s, suzuki m, sugiyama k, yamauchi y, okishige k, goya m, sasano t.A novel catheter ablation strategy for non-paroxysmal atrial fibrillation combining cryoballoon, radiofrequency, and marshall-vein ethanol ablations.Pacing clin electrophysiol.2023 may 2.Doi: 10.1111/pace.14709.Epub ahead of print.Pmid: 37129189.Objective/methods/study data:this study aims to investigate the efficacy and safety of a novel extensive ablation strategy for non-paf, that is based on a combination of cryoballoon (cba), radiofrequency (rfa), and marshall-vein ethanol ablations (ea-vom).The study was a single-center, retrospective observational study.We enrolled 171 consecutive patients who underwent de-novo catheter ablation for nonpaf under conscious sedation with a novel extensive ablation strategy that included cba for pulmonary vein isolation (pvi) and left atrial roof ablation (lara), rfa for mitral isthmus (mi) ablation, superior vena cava isolation, and other linear ablations and ea-vom.Recurrence of atrial arrhythmias over 1 year, procedure outcomes, and procedure-related complications were investigated.:a total of 139 (81.3%) patients remained in sinus rhythm during 1-year followup.Of the 139 patients, 51 patients (29.8%) received antiarrhythmic drugs.The mean procedure time was 204 ± 45 min.Pvi and lara ablation by cba and mi block by rfa and ea-vom were completed in 171 (100%) and 166 (97.1%) patients, respectively.No serious procedure-related complications were observed except for one case of delayed pericardial effusion.Lot, model and catalog number are not available, but the suspected biosense device possibly associated with reported adverse events: thermocool smarttouch sf; biosense webster other biosense webster concomitant devices that were also used in this study: (carto3, biosense webster, diamond bar, ca) non-biosense webster devices that were also used in this study: sheath (agilis, abbott, st.Paul, mn), 28-mm cryoballoon (arctic front advance,medtronic, mn), steerable sheath (flexcath advance, medtronic), mapping catheter (achieve, medtronic), 7fr inner guiding catheter with 90-angled tip (attain select ii sv(6248vi-90s); medtronic), adverse event(s) and provided interventions: qty 17- mild pericardial effusion not requiring drainage qty 1- delayed pericardial effusion requiring drainage qty 10- transient phrenic nerve palsy.
|